No headlines found.
No press releases found.
No news found.
The Defiance Daily Target 2X Long NVO ETF (the "Fund") seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of NOVO Nordisk A/S - ADR (NYSE: NVO) (the "Underlying Security" or "NVO"). NVOX does not invest directly in NOVO. NOVO Nordisk A/S ("Novo Nordisk") is a Danish global pharmaceutical company. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically to provide diabetes care and other chronic conditions like obesity, hemophilia, and growth disorders. It is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The Fund will seek to achieve its objective with respect to Novo Nordisk's American Depositary Receipt (NYSE: NVO).
Defiance Daily Target 2X Long Nvo ETF trades on the ARCA stock market under the symbol NVOX.
As of January 16, 2026, NVOX stock price climbed to $31.71 with 915,135 million shares trading.
NVOX has a beta of 2.91, meaning it tends to be more sensitive to market movements. NVOX has a correlation of 0.14 to the broad based SPY ETF.
NVOX has a market cap of $108.39 million. This is considered a Micro Cap stock.
NVOX has underperformed the market in the last year with a return of -63.2%, while SPY returned +18.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in NVOX shares. However, NVOX has outperformed the market in the last 3 month and 2 week periods, returning +8.6% and +44.9%, while SPY returned +4.4% and +1.5%, respectively. This indicates NVOX has been having a stronger performance recently.
NVOX support price is $25.73 and resistance is $28.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVOX shares will trade within this expected range on the day.
